European Journal of Cancer
Volume 37, Issue 14 , Pages 1746-1751 , September 2001

Willingness-to-pay for colorectal cancer screening

  • E Frew

      Affiliations

    • Research Assistant, Trent Institute for Health Services Research, University of Nottingham, Nottingham, UK
    • ,
  • J.L Wolstenholme

      Affiliations

    • Research Fellow, Health Economics Research Centre, University of Oxford, Oxford, UK
    • ,
  • D.K Whynes

      Affiliations

    • Professor of Health Economics, School of Economics, University of Nottingham, Nottingham NR7 2RD, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44-115-951-5463; fax: +44-115-951-4159

Received 24 April 2001 ,Accepted 25 May 2001.

References 

  1. International Agency for Research on Cancer. Cancer incidence, mortality and prevalence in the European Union, EUCAN 1996 estimates (www.dep.iarc.fr/eucan/eucan.htm), 2000.
  2. Mulcahy HE, Farthing MJG, O'Donoghue DP. Fortnightly review (screening for asymptomatic cancer). BMJ. 1997;314:285–291
  3. Young GP, Macrae FA, St John DJB. Clinical methods for early detection (basis, use and evaluation). In:  Young GP,  Rozen P,  Levin B editor. Prevention and Early Detection of Colorectal Cancer. London: WB Saunders Company Ltd; 1996;p. 242–270
  4. Lieberman D. How to screen for colon cancer. Annu. Rev. Med. 1998;49:163–172
  5. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test. Hemoccult. Br. Med. J. 1998;317:559–565
  6. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–1471
  7. Hardcastle JD, Chamberlain JO, Robinson MHE, et al.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–1477
  8. Gyrd-Hansen D, Sogaard J, Kronborg O. Colorectal cancer screening (efficiency and effectiveness). Health Econom. 1998;7:9–20
  9. Whynes DK, Neilson AR, Walker AR, Hardcastle JD. Faecal occult blood screening for colorectal cancer (is it cost-effective?). Health Econ. 1998;7:21–29
  10. Vernon SW. Participation in colorectal cancer screening (a review). J. Natl Cancer Institute. 1997;89:1406–1422
  11. Brooks A. Pilot bowel screening scheme to start in Britain. BMJ. 1998;317:769
  12. Atkin WS, Cuzick J, Northover JMA, Whynes DK. Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet. 1993;341:736–740
  13. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J. Natl Cancer Inst. 1992;84:1572–1575
  14. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. New Engl. J. Med. 1992;326:653–657
  15. Geul KW, Bosman FT, van Blankenstein M, Grobbee DE, Wilson JHP. Prevention of colorectal cancer (costs and effectiveness of sigmoidoscopy). Scand. J. Gastroenterol. 1997;32(Suppl. 223):79–87
  16. Atkin WS, Hart A, Edwards R, et al.  Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut. 1998;42:560–565
  17. Diener A, O'Brien B, Gafni A. Health care contingent valuation studies (a review and classification of the literature). Health Econom. 1998;7:313–326
  18. Klose T. The contingent valuation method in health care. Health Policy. 1999;47:97–123
  19. Donaldson C, Thomas R, Torgerson DJ. Validity of open-ended and payment scale approaches to eliciting willingness to pay. Appl. Econom. 1997;29:79–84
  20. Smith RD. The discrete-choice willingness to pay question format in health economics (should we adopt environmental guidelines?). Med. Decis. Mak. 2000;20:194–206
  21. Donaldson C, Jones AM, Mapp TJ, Olson JA. Limited dependent variables in willingness to pay studies (applications in health care). Applied Econom. 1998;30:667–677
  22. Office of National Statistics. Distribution of household income, 1995–1998: Regional Trends Dataset RT34802 (www.statistics.gov.uk/statbase/xsdataset.asp), 2000.
  23. Donaldson C. Valuing the benefits of publicly-provided health care (does ‘ability to pay’ preclude the use of ‘willingness to pay’?). Soc. Sci. Med. 1999;49:551–563
  24. Sutton S, Wardle J, Taylor T, et al.  Predictors of attendance in the United Kingdom flexible sigmoidoscopy screening trial. J. Med. Screening. 2000;7:99–104
  25. Neilson AR, Whynes DK. Determinants of persistent compliance with screening for colorectal cancer. Soc. Sci. Med. 1995;41:365–374
  26. Frew E, Wolstenholme JL, Atkin W, Whynes DK. Estimating time and travel costs incurred in clinic-based screening (flexible sigmoidoscopy screening for colorectal cancer). J. Med. Screening. 1999;6:119–123
  27. Walker AR, Whynes DK, Chamberlain JO, Hardcastle JD. The cost of screening for colorectal cancer. J. Epidemiol. Commun. Health. 1991;45:220–224
  28. Walker AR, Whynes DK, Hardcastle JD, Chamberlain JO. The hospital costs of diagnostic procedures for colorectal cancer. J. Clin. Epidemiol. 1991;44:907–914

PII: S0959-8049(01)00200-3

European Journal of Cancer
Volume 37, Issue 14 , Pages 1746-1751 , September 2001

Article Tools

* Image Usage & Resolution